

HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT WITH THE BROKERAGE FIRM KEPLER CHEUVREUX

Paris, France, January 13, 2022 at 06:00 pm CET - ACTICOR BIOTECH (ISIN : FR00140050J5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2021:

- 62,031 shares
- € 191,956.52
- Number of executions on buy side on semester: 264
- Number of executions on sell side on semester: 42
- Traded volume on buy side on semester: 67,876 shares for € 445,195.95
- Traded volume on sell side on semester: 5,845 shares for € 37,412.21

As a reminder the following resources appeared on the liquidity account when the activity started:

- 0 shares
- € 600,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

About ACTICOR BIOTECH

Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), that is developing an innovative treatment for acute thrombotic diseases, including ischemic strokes.

Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab) directed against a novel target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the risk of bleeding, particularly intracerebral hemorrhage.

Acticor Biotech is supported by a panel of European and International Investors (Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris, since November 2021 (ISIN: FR00140050J5 – ALACT).

For further information, please go to www.acticor-biotech.com

Contacts

ACTICOR BIOTECH

Gilles AVENARD, MD

CEO and Founder

gilles.avenard@acticor-biotech.com

T. : +33 (0)6 76 23 38 13

NewCap

Mathilde BOHIN / Olivier BRICAUD

Investor Relations

acticor@newcap.eu

T. : +33 (0)1 44 71 94 95

Sophie BINAY, PhD
General Manager and CSO
Sophie.binay@acticor-biotech.com
T. : +33 (0)6 76 23 38 13

Appendix

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	264	67 876	445 195.95	42	5 845	37 412.21
01/11/2021	37	26 763	189 214.41	-	-	-
02/11/2021	10	4 977	34 639.92	-	-	-
03/11/2021	22	4 799	33 113.10	-	-	-
04/11/2021	14	3 224	21 697.52	-	-	-
05/11/2021	3	450	3 006.00	5	1 500	10 950.00
08/11/2021	-	-	-	8	1 500	10 470.00
09/11/2021	5	1 000	6 850.00	4	23	161.00
10/11/2021	7	1 000	6 870.00	-	-	-
11/11/2021	4	500	3 415.00	-	-	-
12/11/2021	3	358	2 445.14	1	1	6.95
15/11/2021	1	142	969.86	-	-	-
16/11/2021	10	3 509	23 510.30	-	-	-
17/11/2021	4	896	5 850.88	-	-	-
18/11/2021	10	1 000	6 640.00	1	2	13.40
19/11/2021	15	2 650	16 748.00	1	1	6.60
22/11/2021	-	-	-	3	801	5 286.60
23/11/2021	1	400	2 600.00	1	1	6.60
24/11/2021	4	400	2 592.00	1	9	59.40
26/11/2021	6	1 201	7 710.42	2	161	1 046.50
29/11/2021	6	950	5 918.50	-	-	-
30/11/2021	10	1 100	6 677.00	-	-	-
01/12/2021	1	1	5.90	-	-	-
02/12/2021	9	1 270	7 442.20	1	1	5.98
03/12/2021	2	2	11.40	-	-	-
06/12/2021	8	328	1 869.60	-	-	-
07/12/2021	13	1 060	5 808.80	-	-	-
08/12/2021	7	1 325	7 155.00	-	-	-
09/12/2021	-	-	-	3	401	2 245.60
10/12/2021	2	124	669.60	2	501	2 755.50
14/12/2021	7	1 392	7 516.80	-	-	-
15/12/2021	4	400	2 120.00	-	-	-
16/12/2021	7	801	4 213.26	1	1	5.30
17/12/2021	8	1 445	7 239.45	-	-	-
20/12/2021	3	800	3 944.00	-	-	-
21/12/2021	2	555	2 680.65	-	-	-
22/12/2021	5	500	2 365.00	-	-	-
23/12/2021	7	1 000	4 570.00	-	-	-
24/12/2021	-	-	-	2	400	1 880.00
29/12/2021	5	1 000	4 590.00	1	200	932.00
30/12/2021	1	500	2 280.00	2	238	1 097.18
31/12/2021	1	54	246.24	3	104	483.60